{"id":531992,"date":"2021-02-26T20:30:01","date_gmt":"2021-02-26T20:30:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=531992"},"modified":"2021-02-26T20:30:01","modified_gmt":"2021-02-26T20:30:01","slug":"psoriatic-arthritis-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/psoriatic-arthritis-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast_531992.html","title":{"rendered":"Psoriatic Arthritis Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Psoriatic Arthritis Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Psoriatic Arthritis Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the Psoriatic Arthritis, historical and forecasted epidemiology as well as the Psoriatic Arthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Psoriatic arthritis (PsA)<\/strong> is a heterogeneous chronic inflammatory rheumatic disease characterized by pain, stiffness, swollen joints, joint erosion, and bone formation. Clinical manifestations vary greatly between patients. It can present with oligoarticular joint involvement that is typically asymmetric or as a polyarticular disease affecting five or more joints, usually with an asymmetric distribution similar to that of rheumatoid arthritis.<\/p>\n<p style=\"text-align: justify;\">The current practice relies on the individualizing choice of treatment by matching the most severely affected domains of the patients with the best available evidence of efficacies of drugs for those domains. When patients do not respond to treatment, shifting and cycling through different options would be the rational steps.<\/p>\n<p style=\"text-align: justify;\">Get FREE sample copy at:&nbsp;<br \/><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/psoriatic-arthritis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/psoriatic-arthritis-market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">The <strong>Psoriatic Arthritis market report<\/strong> also covers emerging drugs, current treatment practices, Psoriatic Arthritis market share of the individual therapies, current and forecasted Psoriatic Arthritis Market Size from 2017 to 2030 segmented by seven major markets.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The report provides a detailed current <strong>Psoriatic Arthritis treatment practice\/algorithm<\/strong>, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Psoriatic Arthritis Market\" src=\"https:\/\/www.abnewswire.com\/uploads\/7e92ce0763c758ce340397fca890d173.jpg\" alt=\"Psoriatic Arthritis Market\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Psoriatic Arthritis Market Key Facts<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">According to a study by P&eacute;rez et., al (2020), the <strong>prevalence of PsA<\/strong> in Spain was among the highest reported to date, only below that reported in Norway (0.67%) and slightly higher than that reported in Italy (0.42%).<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">According to the National Psoriatic Foundation, about 1 in 3 people or 30% with psoriasis develop psoriatic arthritis (PsA) &ndash; as many as 2.4 million Americans &ndash; and PsA can develop at any age.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">According to a retrospective study of German healthcare insurance data, PsA had prevalence rates of 0.3% respectively, in 2016 (Grellmann et al., 2020)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">As per the estimates by DelveInsight, there is no gender-based difference but the prevalence of severe cases is the highest followed by moderate and mild.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Benefits of Psoriatic Arthritis Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Psoriatic Arthritis market report<\/strong> provides an in-depth analysis of Psoriatic Arthritis Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Psoriatic Arthritis market report will help in developing business strategies by understanding the <strong>Psoriatic Arthritis Market trends &amp; developments<\/strong>, key players, and future market competition that will shape and drive the Psoriatic Arthritis market in the upcoming years.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Psoriatic Arthritis market report covers <strong>Psoriatic Arthritis current treatment practices<\/strong>, emerging drugs, market share of the individual therapies in 7 MM.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides a detailed assessment of the <strong>Psoriatic Arthritis market<\/strong> in terms of market drivers &amp; barriers, Unmet Needs, market opportunities, patient population,&nbsp; comparative analysis of pipeline products with detailed clinical profiles, and other factors.&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/psoriatic-arthritis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Psoriatic Arthritis Market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Psoriatic Arthritis market size<\/strong> is expected to increase during the forecast period owing to the launch of Biosimilars and Biologics as well as the rise in prevalence and expedite R&amp;D.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Psoriatic Arthritis market outlook<\/strong> section of the report helps to build a detailed comprehension of the historic, current and forecasted Psoriatic Arthritis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report gives a thorough detail of the<strong> Psoriatic Arthritis market trend<\/strong> of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Psoriatic Arthritis Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Psoriatic Arthritis epidemiology<\/strong> section covers insights about the historical and current Psoriatic Arthritis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Psoriatic Arthritis Drugs Uptake and Key Market Players<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Psoriatic Arthritis Drugs<\/strong> Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Psoriatic Arthritis market or expected to get launched in the market during the study period. The analysis covers Psoriatic Arthritis market uptake by drugs; patient uptake by therapies; and sales of each drug.&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Report&rsquo;s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.<\/p>\n<p style=\"text-align: justify;\"><strong>Psoriatic Arthritis companies:<\/strong><br \/>Pfizer<br \/>AbbVie<br \/>Sun Pharma<br \/>UCB Biopharma<br \/>Bristol-Myers Squibb<br \/>And many others.<\/p>\n<p style=\"text-align: justify;\"><strong>Psoriatic Arthritis therapies covered in the report include:<\/strong><br \/>Skyrizi<br \/>Ilumya (tildrakizumab-asmn)<br \/>Deucravacitinib<br \/>Rinvoq<br \/>Bimekizumab<br \/>Brepocitinib<br \/>And many more.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Psoriatic Arthritis Competitive Intelligence Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Psoriatic Arthritis Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Psoriatic Arthritis Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Psoriatic Arthritis Patient Journey<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Psoriatic Arthritis Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Psoriatic Arthritis Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Psoriatic Arthritis Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Key Endpoints of Psoriatic Arthritis Treatment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Psoriatic Arthritis Marketed Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Psoriatic Arthritis Emerging Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Psoriatic Arthritis Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Attribute Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Psoriatic Arthritis Market Outlook (7 major markets)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Psoriatic Arthritis Access and Reimbursement Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. KOL Views on the Psoriatic Arthritis Market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Psoriatic Arthritis Market Drivers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Psoriatic Arthritis Market Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em><strong>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports<\/strong><br \/><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/psoriatic-arthritis-epidemiology-forecast?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\">Psoriatic Arthritis Epidemiology Forecast&nbsp;<br \/><\/a><\/strong>DelveInsight&#8217;s Psoriatic Arthritis &#8211; Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Psoriatic Arthritis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/psoriatic-arthritis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\">Psoriatic Arthritis Pipeline Insights<br \/><\/a><\/strong>Psoriatic Arthritis Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Psoriatic Arthritis market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Recent BioPharma Blog &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/blog\/hemophagocytic-lymphohistiocytosis-treatment\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Hemophagocytic Lymphohistiocytosis (HLH) Therapeutics Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<br \/><\/strong><strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=psoriatic-arthritis-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd. 2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=psoriatic-arthritis-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP DelveInsight&#8217;s &#8220;Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the Psoriatic Arthritis, historical and forecasted epidemiology as well as the Psoriatic Arthritis market trends in the United States, EU5 &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/psoriatic-arthritis-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast_531992.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-531992","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531992","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=531992"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531992\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=531992"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=531992"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=531992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}